Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Inclusion Criteria: * Persistent or recurrent cutaneous T-cell lymphoma (CTCL) Stage IB-IVA as defined by TNM staging. * Pathologic proven diagnosis (cytologically confirmed) of CTCL documented in patient history. * Preserved organ function: Creatinine and/or Liver Function levels \<1.5 times institutional upper limits of normal (ULN). * Adequate liver function as indicated by bilirubin \< or equal to 1.5 times ULN, ALT \< or equal to 2 times ULN, AST \< or equal to 2 times ULN. * Albumin \>3.0 g/dL * Adequate renal function as indicated by SCr \< or equal to 2.5 mg/dl. * ECOG performance status between 0-2. * Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period. * Patients over the age of 18 who are willing and able to provide Informed Consent. Exclusion Criteria: * Pathology consistent with peripheral T-cell lymphoma. * Stage IVB (visceral involvement with CTCL, other than lymph node involvement). * History of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection. * Patients who are pregnant or breast feeding. * Allergy to or have history of allergy to diphtheria toxin or IL-2. * Previous ONTAK® usage. * Unstable cardiovascular disease. * Patients who have received systemic or topical antineoplastic therapy or investigational medications within past 14 days. Exception: Clear evidence of disease progression requiring immediate intervention and in the absence of ongoing toxicity from prior therapy. * Ongoing deep vein thrombosis or a diagnosis of deep vein thrombosis less than 3 months prior to protocol enrollment.